SMOFlipid 200 mg/ml is an established four oil lipid mix containing 30% soya-bean oil, 30% medium-chain triglycerides (MCT), 25% olive oil and 15% fish oil.1 It provides energy and essential fatty acids for parenterally fed patients.

Omega-3 fatty acids in parenteral nutrition (PN) have proven benefits for critically ill patients.2 SMOFlipid was the most purchased lipid emulsion brand for parenteral nutrition in the UK in 2020, according to Data Alliance – UK intravenous lipid emulsion sales by unit 2020.3

Find out more about SMOFlipid here:


Four lipid emulsion
SMOFlipid comprises 30% soya-bean oil providing omega-6 fatty acids, 30% medium-chain triglycerides providing rapidly available energy, 25% olive oil providing omega-9 fatty acids and 15% fish oil providing omega-3 fatty acids1

  • Appropriate amount of lipids
    the dose for adults of 1.0–2.0g fat/kg body weight/day (5–10ml/kg body weight/day);1 provides 0.15–0.3g fish oil/kg body weight/day; an omega-6/omega-3 fatty acid ratio of approximately 2.5:14
  • As an individual PN component, can be used to meet recommendations of a maximum of 1.5g lipids/kg/day in critically ill adult patients5 where PN is indicated

Less disruption to markers of immune and metabolic function
compared with standard lipid emulsions even with short-term use2,4,6,7

  • Lower levels of proinflammatory markers compared with an olive/soya-bean oil emulsion and a soya-bean oil emulsion in adult ICU patients4,8
  • Reduces omega-6 fatty acid load compared to lipid emulsions based on soya-bean oil2,9

Less disruption to markers of liver function compared with standard lipid emulsion after four weeks10

  • Less effects on parameters of liver function compared with an olive/soya-bean oil emulsion and a soya-bean emulsion6,7

Omega-3 fatty acids have proven benefits for critically ill patients2,11*

* Compared with standard† PN, hospitalised adults who received omega 3 fatty-acid enriched PN had a:2

  • 40% lower risk of infection (131 vs 215 events; RR 0.60, 95% CI 0.49–0.72; p<0.00001) – Primary endpoint
  • 30-day mortality rate (83 vs 101 events; RR 0.84, 95% CI 0.65–1.07; p=NS)
  • 56% lower risk of sepsis (24 vs 54 events; RR 0.44, 95% CI 0.28–0.70; p=0.0004)
  • Shorter ICU stay (mean stay length reduced by 1.95 days, 95% CI 0.42–3.49; p=0.01)
  • Shorter hospital stay (mean stay length reduced by 2.14 days, 95% CI 1.36–2.93; p<0.00001)

CI = confidence interval; ICU = intensive care unit; gAA = grams amino acids; NS = not significant; PN = parenteral nutrition.

* This was a systematic review and meta-analysis of 49 randomised, controlled trials (3,641 patients). For the primary endpoint of infection rate, 24 studies were included (2,154 patients), 7 of these were in ICU patients and 17 in non-ICU patients. Thirty-day mortality was a co-primary outcome reported in 20 of the trials.2
†non-ω-3 fatty acid enriched

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Fresenius Kabi Limited.